Evidence-Based Summary
There is no published randomized trial comparing retatrutide with tirzepatide. In its own placebo-controlled phase 3 trial (TRIUMPH-1, 80 weeks, adults with obesity without diabetes), retatrutide groups lost on average 17.6% to 25.0% of body weight versus 3.9% with placebo. In tirzepatide's SURMOUNT-1 trial (72 weeks, a similar population), tirzepatide groups lost 15.0% to 20.9% versus 3.1% with placebo. These figures come from different trials, with different durations, sites and participants, so they are not directly comparable. Tirzepatide is FDA-approved, has a cardiovascular outcomes trial and years of prescribing experience; retatrutide is not approved and its outcomes trial is still running. The head-to-head TRIUMPH-5 trial is the study designed to answer which produces more weight loss.
Quick Comparison: Retatrutide vs Tirzepatide
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Class | Investigational triple agonist (one molecule acting on three hormone receptors) | Approved dual incretin receptor agonist |
| Target receptors | GIP, GLP-1 and glucagon receptors | GIP and GLP-1 receptors |
| How it is given | Once-weekly injection under the skin in clinical trials only | Once-weekly injection under the skin (Mounjaro, Zepbound) |
| U.S. regulatory status (October 2026) | Not FDA-approved; investigational. FDA says it cannot be used in compounding | FDA-approved for type 2 diabetes (Mounjaro) and for defined weight-management and sleep-apnea uses (Zepbound) |
| Strongest human evidence | Phase 3 placebo-controlled trials (TRIUMPH-1, TRIUMPH-2) | Multiple phase 3 trials, including direct comparisons with semaglutide and a cardiovascular outcomes trial against dulaglutide |
| Main safety concerns | Gastrointestinal effects; heart-rate rise, low blood pressure and abnormal skin sensations (dysesthesia) reported; long-term safety unknown | Gastrointestinal effects; label warnings including pancreatitis and gallbladder disease, and a boxed warning based on rodent thyroid C-cell tumors |
| Direct comparison | TRIUMPH-5 (retatrutide vs tirzepatide) registered and active, not recruiting; no results published | Same trial; no results published |
| WADA status (2026 List) | Not named; as a drug with no regulatory approval it may fall under S0 (non-approved substances) | Not named on the 2026 Prohibited List |
Three Receptors vs Two: How Retatrutide and Tirzepatide Differ
GIP and GLP-1 are gut hormones (incretins) that help release insulin after meals and reduce appetite. Glucagon is a pancreatic hormone that raises blood sugar but also increases energy use and liver fat burning. Adding a receptor target changes the pharmacology; it does not by itself prove a better clinical result.
Retatrutide
Primary Target: GIP, GLP-1 and glucagon receptors
Affinity Profile: Triple agonist; in lab assays, strongest at the GIP receptor and more balanced at glucagon and GLP-1 receptors
In obese mice, the glucagon-receptor component added higher energy expenditure to the reduced food intake driven by GIP and GLP-1 signalling. These are animal and cell findings; human trials measure the drug as a whole.
Tirzepatide
Primary Targets: GIP and GLP-1 receptors
Affinity Profile: Dual agonist
Activates both incretin receptors, lowering blood glucose and reducing food intake. Human trials do not isolate how much of the effect comes from each receptor.
FDA Status: One Approved Medicine, One Investigational Drug
United States status checked 11 October 2026. Approval belongs to a named product and its labelled uses.
Retatrutide Status & Formulations
Not FDA-approved. No retatrutide product appears in Drugs@FDA. FDA states that retatrutide is not a component of any FDA-approved drug, has not been found safe and effective for any condition and cannot be used in compounding; the agency has warned companies selling it as a "research" product.
Tirzepatide Status & Formulations
Mounjaro is approved for glycemic control in adults and children aged 10 years and older with type 2 diabetes. Zepbound is approved for defined adult weight-management indications and for moderate-to-severe obstructive sleep apnea in adults with obesity. Each label has its own eligibility criteria.
Critical Regulatory Distinction
Phase 3 success is not approval. Products sold online as retatrutide are unapproved and are not the material tested in clinical trials. Compounded tirzepatide is not an FDA-approved equivalent of Mounjaro or Zepbound.
TRIUMPH vs SURMOUNT: Separate Trial Programs
Each drug has been tested mainly against placebo. Placebo-controlled results from different trials cannot be ranked against each other as if they were one study.
Retatrutide: Clinical Evidence Overview
TRIUMPH-1 randomized 2,339 adults with obesity and without diabetes for 80 weeks. Mean weight change was −17.6%, −23.7% and −25.0% across the three retatrutide groups versus −3.9% with placebo; knee-pain and sleep-apnea measures also improved in subgroups. TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes: weight change was −11.9% to −18.8% versus −5.1% with placebo at 80 weeks. Both were funded by Eli Lilly. A cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) is ongoing.
Tirzepatide: Clinical Evidence Overview
SURMOUNT-1 randomized 2,539 adults with obesity or overweight without diabetes for 72 weeks; mean weight change was −15.0%, −19.5% and −20.9% across tirzepatide groups versus −3.1% with placebo. In SURMOUNT-5, tirzepatide produced greater mean weight loss than semaglutide (−20.2% vs −13.7%). SURPASS-CVOT showed tirzepatide was noninferior, but not superior, to dulaglutide for major cardiovascular events in type 2 diabetes. All were funded by Eli Lilly.
Curated Clinical Evidence Table
A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.
| Study & Citation | Population | Comparison & Dosing | Duration | Main Endpoint | Key Finding | Methodological Limitations |
|---|---|---|---|---|---|---|
| TRIUMPH-1 (Jastreboff et al., NEJM 2026) | 2,339 adults with obesity, without diabetes | Retatrutide (three dose groups) vs placebo | 80 weeks | Percent change in body weight; knee pain and sleep-apnea subgroups | −17.6% to −25.0% with retatrutide vs −3.9% with placebo. | Placebo-controlled; not a comparison with tirzepatide. Industry funded. |
| TRIUMPH-2 (Bellido et al., Lancet 2026) | 1,152 adults with obesity and type 2 diabetes | Retatrutide (three dose groups) vs placebo | 80 weeks | Percent change in body weight | −11.9% to −18.8% with retatrutide vs −5.1% with placebo. | Hypotension and dysesthesia more common than with placebo; discontinuation for adverse events or death up to 12% vs 5%. |
| Retatrutide phase 2 (Jastreboff et al., NEJM 2023) | 338 adults with obesity or overweight with a weight-related condition | Retatrutide (several dose groups) vs placebo | 48 weeks | Percent change in body weight | −8.7% to −24.2% at 48 weeks vs −2.1% with placebo. | Small dose-finding trial; dose-dependent heart-rate increases peaked at 24 weeks. |
| SURMOUNT-1 (Jastreboff et al., NEJM 2022) | 2,539 adults with obesity or overweight, without diabetes | Tirzepatide (three dose groups) vs placebo | 72 weeks | Percent change in body weight | −15.0% to −20.9% with tirzepatide vs −3.1% with placebo. | Different trial, duration and sites from TRIUMPH-1; not directly comparable. |
| SURMOUNT-5 (Aronne et al., NEJM 2025) | 751 adults with obesity, without diabetes | Tirzepatide vs semaglutide | 72 weeks | Percent change in body weight | −20.2% vs −13.7% (P<0.001). | Open-label; does not include retatrutide. |
| TRIUMPH-5 (NCT06662383, registry record) | Adults with obesity; estimated 800 participants | Retatrutide vs tirzepatide, double-blind | Not yet reported | Efficacy and safety (registry) | Active, not recruiting; no results posted or published as of 11 October 2026. | The only direct comparison; results pending. |
Adverse Effects: Known Label vs Trial-Only Data
Tirzepatide's safety profile is described in an FDA label built on large trials and post-marketing experience. Retatrutide's safety data come only from clinical trials, and longer-term effects are unknown.
Tirzepatide only: Boxed Warning for thyroid C-cell tumors
Tirzepatide labels carry a boxed warning because thyroid C-cell tumors occurred in rodents; whether this happens in humans is unknown, and tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Retatrutide has no FDA label, so no labelled warnings exist for it; that is not evidence that it is safer.
| Safety Consideration | Retatrutide | Tirzepatide |
|---|---|---|
| Most common adverse effects | Gastrointestinal: diarrhoea, nausea, vomiting; dose-related in phase 2 | Gastrointestinal: nausea, diarrhoea, vomiting, mostly during dose escalation |
| Cardiovascular signals | Dose-dependent heart-rate increase in phase 2; hypotension more frequent than placebo in TRIUMPH-2 | Zepbound label reports a mean heart-rate increase of 1 to 3 beats per minute vs placebo; SURPASS-CVOT noninferior to dulaglutide for major cardiovascular events |
| Other reported effects | Dysesthesia (abnormal skin sensations) more common than placebo in TRIUMPH-2 | Zepbound label also reports dysesthesia more often than placebo; warnings include pancreatitis, gallbladder disease, dehydration-related kidney injury and hypoglycemia with insulin or an insulin secretagogue |
| Stopping because of side effects | TRIUMPH-2: up to 12% in one retatrutide group vs 5% with placebo (adverse events or death) | SURMOUNT-1: 4.3% to 7.1% across tirzepatide groups vs 2.6% with placebo |
| Long-term outcomes | Unknown; TRIUMPH-Outcomes ongoing | Cardiovascular outcomes trial completed versus an active comparator |
Specific Drug Interaction Note
Tirzepatide labels advise a non-oral contraceptive method or an added barrier method for four weeks after starting and after each dose increase, because slowed stomach emptying can reduce oral contraceptive absorption. Whether retatrutide has a similar interaction has not been established in a label.
What Retatrutide and Tirzepatide Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Shared incretin targets
Both activate GIP and GLP-1 receptors and are given as once-weekly injections.
Same developer, similar trial designs
Both were developed and funded by Eli Lilly, with placebo-controlled programs in obesity and type 2 diabetes.
Gastrointestinal side effects dominate
Nausea, diarrhoea and vomiting are the most common adverse events for both.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Glucagon receptor
Retatrutide also activates the glucagon receptor, which in animal studies raises energy expenditure; tirzepatide does not.
Approval and experience
Tirzepatide is FDA-approved with years of prescribing data; retatrutide is investigational.
Outcomes data
Tirzepatide has a completed cardiovascular outcomes trial; retatrutide's is ongoing.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Retatrutide is a stronger, next-generation tirzepatide
UnprovenRetatrutide is not FDA-approved for any use.
Retatrutide's trial weight losses are numerically larger than tirzepatide's in separate trials, but different trials are not directly comparable. The direct comparison, TRIUMPH-5, has not reported.
"Research" retatrutide bought online is the same drug used in the trials
Not supportedFDA states retatrutide cannot be used in compounding and is not a component of any approved drug.
FDA has warned companies selling unapproved retatrutide labelled for research. Identity, purity and sterility of such products are not verified, and trial results do not apply to them.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Weight reduction in adults with obesity
Retatrutide has two positive phase 3 trials but no approval or long-term data; tirzepatide has multiple phase 3 trials and an approved label.
Glucose control in type 2 diabetes
Retatrutide improved glucose in TRIUMPH-2 and TRANSCEND-T2D-1; tirzepatide is approved for type 2 diabetes.
Cardiovascular outcomes
No retatrutide outcome results yet; tirzepatide was noninferior, not superior, to dulaglutide in SURPASS-CVOT.
Retatrutide vs tirzepatide directly
No published head-to-head trial.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Direct comparison
TRIUMPH-5 compares retatrutide with tirzepatide; its results are needed before any claim of superiority.
Long-term safety and outcomes
TRIUMPH-Outcomes is testing cardiovascular and kidney outcomes. The heart-rate rise and dysesthesia signals need longer follow-up.
What the glucagon component adds in people
The extra energy-expenditure effect comes mainly from animal studies; how much it contributes in humans is not settled.
Industry funding
All the trials summarized here were funded by the manufacturer, Eli Lilly. Independent replication is limited.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Phase 3 randomized controlled trial
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityTRIUMPH-1; funded by Eli Lilly.
-
Phase 3 randomized controlled trial
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trialFunded by Eli Lilly.
-
Phase 2 randomized controlled trial
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
-
Phase 3 randomized controlled trial
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
-
Discovery and phase 1 study
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptReceptor pharmacology and mouse data.
-
Preclinical & molecular pharmacology
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
-
Phase 3 randomized controlled trial
Tirzepatide Once Weekly for the Treatment of ObesitySURMOUNT-1; funded by Eli Lilly.
-
Phase 3 randomized controlled trial · Head-to-head
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
-
Cardiovascular outcomes trial
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
-
Registry record
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityTRIUMPH-5; phase 3, active, not recruiting; estimated 800 participants; sponsor Eli Lilly. Checked 11 October 2026.
-
Registry record
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
-
FDA safety communication
FDA's concerns with unapproved GLP-1 drugs used for weight loss
-
Official U.S. prescribing information
Zepbound, current label
-
Official U.S. prescribing information
Mounjaro, current label